Difference between revisions of "Part:BBa K4165143"
Line 3: | Line 3: | ||
<partinfo>BBa_K4165143 short</partinfo> | <partinfo>BBa_K4165143 short</partinfo> | ||
− | + | A synthetic peptide that is used for targeting misfolded tau protein (BBa_K4165009) as it binds to PHF6 of tau fibrils. | |
===Usage and Biology=== | ===Usage and Biology=== | ||
− | KNT is a peptide tested as an inhibitor for tau aggregation. Its half maximal concentration for tau fibril formation inhibition is 182.8 μM, it can bind to tau at PHF seed (VQIVYK) | + | KNT (KNTPQHRKLRLS) is a peptide tested as an inhibitor for tau aggregation. Its half maximal concentration for tau fibril formation inhibition is 182.8 μM, and it can bind to tau at PHF seed (VQIVYK). The peptide can penetrate cell membrane and cytosol of N2a cells |
Latest revision as of 13:19, 11 October 2022
KNT Peptide
A synthetic peptide that is used for targeting misfolded tau protein (BBa_K4165009) as it binds to PHF6 of tau fibrils.
Usage and Biology
KNT (KNTPQHRKLRLS) is a peptide tested as an inhibitor for tau aggregation. Its half maximal concentration for tau fibril formation inhibition is 182.8 μM, and it can bind to tau at PHF seed (VQIVYK). The peptide can penetrate cell membrane and cytosol of N2a cells
Sequence and Features
Assembly Compatibility:
- 10COMPATIBLE WITH RFC[10]
- 12COMPATIBLE WITH RFC[12]
- 21COMPATIBLE WITH RFC[21]
- 23COMPATIBLE WITH RFC[23]
- 25COMPATIBLE WITH RFC[25]
- 1000COMPATIBLE WITH RFC[1000]
Reference
1. Dammers, C., Yolcu, D., Kukuk, L., Willbold, D., Pickhardt, M., Mandelkow, E., ... & Funke, S. A. (2016). Selection and Characterization of Tau Binding ᴅ-Enantiomeric Peptides with Potential for Therapy of Alzheimer Disease. PLoS One, 11(12), e0167432.